Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study

@article{Walter2000CreatineMI,
  title={Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study},
  author={Mosquera Walter and Hanns Lochm{\"u}ller and Peter Reilich and Thomas Klopstock and R Huber and Manfred Hartard and Michael Hennig and Dieter E. Pongratz and Wolfgang M{\"u}ller-Felber},
  journal={Neurology},
  year={2000},
  volume={54},
  pages={1848 - 1850}
}
Article abstract The authors assessed the safety and efficacy of creatine monohydrate (Cr) in various types of muscular dystrophies in a double-blind, crossover trial. Thirty-six patients (12 patients with facioscapulohumeral dystrophy, 10 patients with Becker dystrophy, 8 patients with Duchenne dystrophy, and 6 patients with sarcoglycan-deficient limb girdle muscular dystrophy) were randomized to receive Cr or placebo for 8 weeks. There was mild but significant improvement in muscle strength… 

Figures from this paper

Creatine monohydrate in myotonic dystrophy

Abstract. We assessed safety and efficacy of creatine monohydrate (Cr) in myotonic dystrophy (DM1) in a double-blind, cross-over trial. Thirty-four patients with defined DM1 were randomized to

Creatine monohydrate in DM2/PROMM

There were no significant differences of muscle strength as assessed by hand-held dynamometry, testing of maximum grip strength, Medical Research Council scoring, and the Neuromuscular Symptom Score between the two groups.

A placebo-controlled crossover trial of creatine in mitochondrial diseases

Article abstract To test the efficacy and safety of creatine (Cr) monohydrate in mitochondrial diseases, 16 patients with chronic progressive external ophthalmoplegia or mitochondrial myopathy were

Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial

This is the first clinical trial evaluating creatine therapy in SBMA and it is expected that recovery of intramuscular creatine concentration is expected to improve muscle strength.

Beneficial effects of creatine supplementation in dystrophic patients

Cr may provide some symptomatic benefit in these patients with Duchenne muscular dystrophy, and urinary excretion of collagen type I cross‐linking N‐telopeptide declined to about one third after Cr, and no adverse effect was observed.

Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy

Four months of CrM supplementation led to increases in FFM and handgrip strength in the dominant hand and a reduction in a marker of bone breakdown and was well tolerated in children with DD.

Creatine monohydrate does not increase strength in patients with hereditary neuropathy

The potential benefits of short-term Creatine monohydrate supplementation for patients with hereditary motor sensory neuropathy (HMSN) type I and II are evaluated.

Creatine as a therapeutic strategy for myopathies

The evidence for side effects or negative impact upon serological metrics from creatine supplementation in all groups of myopathy patients is almost non-existent and pale in comparison to the very substantial and well-known side effects from the current chemotherapeutic interventions for some myopathies (i.e., corticosteroids).

Duchenne muscular dystrophy

There is no evidence that steroids are associated with prolonged life or with improved pulmonary or cardiac function in DMD, and it is clear that the risk of side effects increases with duration of use of oral steroids.
...

References

SHOWING 1-10 OF 12 REFERENCES

Creatine monohydrate increases strength in patients with neuromuscular disease

Short-term creatine monohydrate increased high-intensity strength significantly in patients with neuromuscular disease and increased all measured indices in both studies.

A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies

It is concluded that creatine monohydrate increased the strength of high‐intensity anaerobic and aerobic type activities in patients with mitochondrial cytopathies but had no apparent effects upon lower intensity aerobic activities.

31P NMR studies in Duchenne muscular dystrophy

To evaluate possible progressive metabolic changes in Duchenne muscular dystrophy, we used 31P nuclear magnetic resonance spectroscopy to measure high-energy phosphate compounds and phosphorylated

Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin

Intravenous immunoglobulin is the first treatment modality to improve the strength of some muscles in patients with this disabling inflammatory myopathy and the unexpected but encouraging results from this pilot study warrant a controlled trial.

Cellular energetics of dystrophic muscle

Muscular dystrophy: historical overview and classification in the genetic era.

A historical perspective is presented on the classification of the muscular dystrophies, and the underpinnings of a genetic classification that can be used both at the bedside and in the research laboratory are furnished.

Effect of oral creatine supplementation on jumping and running performance.

The results show that Cr supplementation helps to prolong the time during which the maximal rate of power output could be maintained and the time of intensive running up to exhaustion improved by 13%.

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis

It was found that oral administration of creatine produced a dose-dependent improvement in motor performance and extended survival in G93A transgenic mice, and it protected mice from loss of both motor neurons and substantia nigra neurons at 120 days of age.

Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)

  • Neurology
  • 1993